Grufity logoGrufity logo

CRBP

0.13USD-0.02(-13.22%)Market Closed

Corbus Pharmaceuticals Holdings Inc

Market Summary

USD0.13-0.02Market Closed
-13.22%

CRBP Stock Price

RSI Chart

Valuation

Market Cap

16.0M

Price/Earnings

-0.46

Price/Sales

19.11

Price/Cashflow

-0.51

Price/Sales

Profitability

Return on Equity

-71%

Return on Assets

-42.8%

Fundamentals

Revenue

Earnings

Earnings (TTM)

-41.7M

Earnings Y/Y

-303.54%

Earnings Q/Q

33.72%

Price Action

52 Week Range

0.100.87
(Low)(High)

Last 7 days

14.0%

Last 30 days

3.6%

Last 90 days

-34.4%

Trailing 12 Months

-84.1%

Financial Health

Current Ratio

4.81

Debt/Equity

0.43

Debt/Cashflow

-1.5

Investor Care

Shares Dilution (1Y)

0.04%

Diluted EPS (TTM)

-0.29

Peers (Alternatives to Corbus Pharmaceuticals Holdings)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
13.24% 45.49%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
13.13% -41.64%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
3.50% 20.88%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
3.66% 57.19%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
9.35% 28.19%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
9.82% 47.16%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
11.31% 51.76%
-19.93
12.09
35.70% -47.34%
MID-CAP
4.1B
-
-3.30% 6.13%
-18.85
63.29
26.15% -23.38%
3.8B
-
48.10% -29.78%
-5.86
917.1
-74.20% -52.72%
3.2B
272.3M
6.14% -50.33%
-4.51
13.74
-18.36% -74.56%
2.9B
334.3M
-1.03% -49.23%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.5B
191.8M
27.64% 144.62%
26.77
8.56
43.59% 60.82%
1.3B
504.0K
12.76% -3.22%
-4.91
2.5K
-66.53% -10.64%
306.1M
66.9M
42.27% -60.18%
-1.4
4.57
-43.57% -69.06%
16.0M
-
3.64% -84.06%
-0.46
19.11
-77.61% 5.14%

Financials for Corbus Pharmaceuticals Holdings

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32021Q42021Q32021Q22021Q1
Revenue-100.0%null1233
Operating Expenses-31.4%395768
  S&GA Expenses-12.5%141622
  R&D Expenses-66.9%103147
Net Income8.6%-41.73-45.64-43.99
* denotes actual numbers (not divided by Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-10.0%748296108120
  Current Assets-10.5%677588100112
    Cash Equivalents-51.7%1226572537
  Net PPE-9.6%22223
Liabilities-2.2%3233353942
  Current Liabilities11.8%1716151717
  Long Term Debt0%2121212121
    LT Debt, Current32.2%10753-
    LT Debt, Non Current-19.2%912141619
Shareholder's Equity-15.2%4249616978
  Retained Earnings-2.4%-381.20-372.42-359.17-349.73-339.47
  Additional Paid-In Capital0.3%423422420419417
Accumulated Depreciation7.0%33323
Shares Outstanding0.0%125125125125125
Float-202----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-25.6%-39.79-31.69-36.99-48.18-56.71
  Share Based Compensation-16.7%678910
Cashflow From Investing-29.3%152127-73.42-70.19
Cashflow From Financing-100.0%1*006182
* denotes actual numbers (not divided by Millions)

Risks

What is the probability of a big loss on CRBP?

100%


Probability that Corbus Pharmaceuticals Holdings stock will be more than 20% underwater in next one year

100%


Probability that Corbus Pharmaceuticals Holdings stock will be more than 30% underwater in next one year.

83.5%


Probability that Corbus Pharmaceuticals Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CRBP drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Corbus Pharmaceuticals Holdings was unfortunately bought at previous high price.

Returns

Cumulative Returns on CRBP

-30.6%


7-Year Cumulative Returns

-55.8%


5-Year Cumulative Returns

-69.8%


3-Year Cumulative Returns

What are the long-term rolling returns for CRBP?

FIve years rolling returns for Corbus Pharmaceuticals Holdings.

Which funds bought or sold CRBP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-
-
-%
2022-11-15
JANE STREET GROUP, LLC
SOLD OFF
-100
-21,000
-
-%
2022-11-15
MERCER GLOBAL ADVISORS INC /ADV
UNCHANGED
-
-3,000
5,000
-%
2022-11-15
Neuberger Berman Group LLC
UNCHANGED
-
-2,000
3,000
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
UNCHANGED
-
-9
16
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
STATE STREET CORP
UNCHANGED
-
-35,000
65,000
-%
2022-11-14
ROYAL BANK OF CANADA
ADDED
31,003
5,000
5,000
-%
2022-11-14
Bank of New York Mellon Corp
UNCHANGED
-
-4,000
5,000
-%
2022-11-14
TWO SIGMA INVESTMENTS, LP
ADDED
59.55
1,000
20,000
-%

1–10 of 43

Latest Funds Activity

Are funds buying CRBP calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own CRBP

Corbus Pharmaceuticals Holdings News

Investing.com UK

Why Dollar General Shares Are Trading Lower By Over 8%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session By Benzinga.3 days ago

CRBP Fair Value

Recent SEC filings of Corbus Pharmaceuticals Holdings

View All Filings
Date Filed Form Type Document
Nov 14, 2022
DEF 14A
DEF 14A
Nov 08, 2022
10-Q
Quarterly Report
Nov 04, 2022
PRE 14A
PRE 14A
Oct 31, 2022
8-K
Current Report
Oct 12, 2022
8-A12G
8-A12G
Oct 12, 2022
8-K
Current Report
Sep 28, 2022
3
Insider Trading
Sep 28, 2022
4
Insider Trading
Sep 26, 2022
8-K
Current Report
Aug 24, 2022
SC 13G/A
Major Ownership Report

Latest Insider Trading transactions for CRBP

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-08-10
Cohen Yuval
BOUGHT
1,003.2
0.264
3,800
Chief Executive Officer
2022-08-10
Millian Craig Stuart
BOUGHT
1,272.5
0.2545
5,000
Chief Operating Officer
2022-08-10
Moran Sean F.
BOUGHT
5,198
0.2599
20,000
Chief Financial Officer
2022-05-16
Cohen Yuval
BOUGHT
2,625
0.25
10,500
Chief Executive Officer
2022-05-16
Moran Sean F.
BOUGHT
3,600
0.3
12,000
Chief Financial Officer
2022-03-10
Millian Craig Stuart
BOUGHT
3,700
0.37
10,000
Chief Operating Officer
2022-03-10
Moran Sean F.
BOUGHT
5,550
0.37
15,000
Chief Financial Officer
2022-03-09
Cohen Yuval
BOUGHT
3,182
0.37
8,600
Chief Executive Officer
2020-12-21
Moran Sean F.
SOLD
-153,125
1.75
-87,500
Chief Financial Officer
2020-12-21
Moran Sean F.
ACQUIRED
122,500
1.4
87,500
Chief Financial Officer

1–10 of 38

Yuval Cohen
40
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

CRBP Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Revenue from awards$ 0$ 97,323$ 0$ 881,705
Operating expenses:    
Research and development4,108,1908,695,6419,894,06830,681,684
General and administrative4,073,2665,277,09014,144,55716,190,684
Litigation Settlement005,000,0000
Total operating expenses8,181,45613,972,73129,038,62546,872,368
Operating loss(8,181,456)(13,875,408)(29,038,625)(45,990,663)
Other income (expense), net:    
Other income (expense), net77,71212,033,031(324,322)11,790,328
Interest income (expense), net(541,889)(391,867)(1,491,137)(1,439,587)
Change in fair value of derivative liability0472,1430670,143
Foreign currency exchange gain (loss), net(136,087)(414,048)(613,766)(409,914)
Other income (expense), net(600,264)11,699,259(2,429,225)(10,610,970)
Net loss$ (8,781,720)$ (2,176,149)$ (31,467,850)$ (35,379,693)
Earnings Per Share, Basic$ (0.07)$ (0.02)$ (0.25)$ (0.29)
Earnings Per Share, Diluted$ (0.07)$ (0.02)$ (0.25)$ (0.29)
Weighted Average Number of Shares Outstanding, Basic125,268,381125,209,985125,255,927122,234,847
Weighted Average Number of Shares Outstanding, Diluted125,268,381125,209,985125,255,927122,234,847
Comprehensive loss:    
Net loss$ (8,781,720)$ (2,176,149)$ (31,467,850)$ (35,379,693)
Other comprehensive income (loss):    
Change in unrealized gain (loss) on marketable debt securities(87,554)(3,513)(144,429)(8,967)
Total other comprehensive income (loss)(87,554)(3,513)(144,429)(8,967)
Total comprehensive loss$ (8,869,274)$ (2,179,662)$ (31,612,279)$ (35,388,660)

CRBP Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 12,443,645$ 25,006,632
Investments53,785,55972,640,520
Restricted cash192,475192,475
Prepaid expenses and other current assets926,1612,365,010
Total current assets67,347,840100,204,637
Restricted cash477,425477,425
Property and equipment, net1,798,2122,392,696
Operating lease right of use assets4,074,0744,609,110
Other assets133,05546,385
Total assets73,830,606107,730,253
Current liabilities:  
Notes payable0767,938
Accounts payable1,374,2201,782,277
Accrued expenses4,833,83910,093,312
Derivative liability133,710133,710
Operating lease liabilities, current1,243,8021,136,948
Current portion of long-term debt9,883,6383,093,344
Total current liabilities17,469,20917,007,529
Long-term debt, net of debt discount9,385,84715,636,275
Other long-term liabilities22,20522,205
Operating lease liabilities, noncurrent5,007,2365,956,217
Total liabilities31,884,49738,622,226
Stockholders' equity  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2022 and December 31, 202100
Common stock, $0.0001 par value; 300,000,000 shares authorized, 125,280,881 and 125,230,881 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively12,52812,523
Additional paid-in capital423,342,069418,891,713
Accumulated deficit(381,201,614)(349,733,764)
Accumulated other comprehensive loss(206,874)(62,445)
Total stockholders’ equity41,946,10969,108,027
Total liabilities and stockholders’ equity$ 73,830,606$ 107,730,253